Cochlear Limited (CHEOF)
OTCMKTS · Delayed Price · Currency is USD
185.99
0.00 (0.00%)
Feb 5, 2026, 4:00 PM EST
Cochlear Revenue
In the fiscal year ending June 30, 2025, Cochlear had annual revenue of 2.34B AUD with 4.81% growth. Cochlear had revenue of 1.17B in the half year ending June 30, 2025, with 11.46% growth.
Revenue
2.34B AUD
Revenue Growth
+4.81%
P/S Ratio
7.47
Revenue / Employee
426.02K AUD
Employees
5,500
Market Cap
11.47B USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 2.34B | 107.50M | 4.81% |
| Jun 30, 2024 | 2.24B | 299.50M | 15.47% |
| Jun 30, 2023 | 1.94B | 287.80M | 17.46% |
| Jun 30, 2022 | 1.65B | 150.70M | 10.06% |
| Jun 30, 2021 | 1.50B | 177.00M | 13.40% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zomedica | 29.45M |
| OpGen | 9.00M |
| Tian'an Technology Group | 2.12M |
| PetVivo Holdings | 1.41M |
| Positron | 486.45K |
| Guided Therapeutics | 178.00K |
| CS Diagnostics | 98.73K |
| Vivos | 48.62K |
Cochlear News
- 25 days ago - LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Cochlear Ltd (COH) - GuruFocus
- 4 weeks ago - Cochlear Announces Availability of Nucleus Nexa System to US Military Veterans - PRNewsWire
- 2 months ago - MRI 3T Cochlear Implant Market Poised for 9.96% CAGR Growth, North America Leads - GlobeNewsWire
- 2 months ago - Saluda Medical shares sink in worst ASX debut in decades - The Australian Financial Review
- 2 months ago - MED-EL Cochlear Implant Becomes First FDA-Approved Option for Children Seven Months and Older - Business Wire
- 2 months ago - Saluda Medical set for $775m ASX debut - The Australian Financial Review
- 3 months ago - Brokers throw open $125m Epiminder IPO book; Cochlear in for $10m - The Australian Financial Review
- 6 months ago - Cochlear reports FY results - Seeking Alpha